At ASCO GU 2026, new data highlighted the growing role of HIF inhibitors in kidney cancer. Dr. Brian Rini reviews results from LITESPARK-011, showing improved progression-free survival with lenvatinib plus belzutifan, and LITESPARK-022, which evaluated belzutifan added to adjuvant pembrolizumab. He also discusses early phase 2 findings for the next-generation HIF inhibitor casdatifan. Together, these studies reinforce HIF inhibition as an emerging strategy across multiple RCC treatment settings.
ARROS-1 Trial: Zidesamtinib Demonstrates Activity in TKI-Pretreated ROS1-Positive NSCLC
Nuvalent announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for zidesamtinib for
